Efficacy of commercial genotype 1 porcine reproductive and respiratory syndrome virus (PRRSV) vaccine against field isolate of genotype 2 PRRSV
| Autor: | Young S. Lyoo, Sun Young Sunwoo, Seong-sik Ko, Myung-Hyee Kim, Sang won Seo, Sung J. Yoo |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Genotype Swine 040301 veterinary sciences animal diseases viruses Immunology Porcine Reproductive and Respiratory Syndrome Enzyme-Linked Immunosorbent Assay Viremia Antibodies Viral Virus 0403 veterinary science 03 medical and health sciences Immunity medicine Animals Porcine respiratory and reproductive syndrome virus Avidity Neutralizing antibody General Veterinary biology virus diseases Viral Vaccines 04 agricultural and veterinary sciences Porcine reproductive and respiratory syndrome virus biology.organism_classification medicine.disease Antibodies Neutralizing Virology Specific Pathogen-Free Organisms Vaccination 030104 developmental biology biology.protein Cytokines Viral load |
| Zdroj: | Veterinary Immunology and Immunopathology. 172:43-49 |
| ISSN: | 0165-2427 |
| DOI: | 10.1016/j.vetimm.2016.02.016 |
| Popis: | Although several recent studies have found that type 1 porcine reproductive and respiratory syndrome virus (PRRSV) modified live virus (MLV) vaccine showed appreciable levels of cross-protection against type 2 PRRSV infection, the possibility of cross-protection between two genotype of PRRSV is still controversial. To determine potential protective efficacy against hetero-genotype field strain of PRRSV and to improve understandings of the mechanisms underlying performance improvement after infection in vaccinated animals, piglets were vaccinated with type 1 PRRSV MLV vaccine and challenged with type 2 field strain of PRRSV. As a result, vaccinated animals gained on average 8.45 kg in comparison to 4.77 kg measured in non-vaccinated animals during a 3-week period after viral challenge, which shows using a certain PRRSV vaccine could be clinically effective against heterologous genotypic virus challenge. In vaccinated animals, viremia was reduced and cleared rapidly, whilst viral load was much higher and reduced more slowly, indicating rebound viremia in non-vaccinated animals. The titers of neutralizing antibody against the type 2 PRRSV did not exceed the protective level in any animal from both vaccinated and control groups. Instead, antibody avidity of vaccinated animals was much higher than in the control group clearly. Furthermore, a strong negative correlation between antibody avidity and viremia was noted in 80% of vaccinated animals. Through those results from tests evaluating degree of antibody maturation and its relevance with clearing viremia, it could be suggested that non-neutralizing antibodies induced by vaccination prior to challenge might play a key role in protection against PRRSV infection, especially in early time course. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect